-
10 Feb ' 08:16
COLUMBIA, Md.--(BUSINESS WIRE)--Feb 10, 2012 - Osiris Therapeutics, Inc., today provided an update on the status of the development and commercialization agreement with Genzyme, a Sanofi company.PITTSBURGH, Feb. 10, 2012 (PITTSBURGH TRIBUNE REVIEW) - Mylan Inc. CEO Heather Bresch urged Washington lawmakers today to approve a new $300 million a year fee on the generic drug industry and to update a law that will give federal regulators greater power to inspect foreign pharmaceutical facilities.Clarksburg, MD, February 9, 2012—“In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer’s disease,” said Stacy Pagos Haller, President and CEO of the American Health Assistance Foundation (AHAF), a nonprofit that identifies and funds exceptionally high-impact research worldwide through its Alzheimer’s Disease Research program.HYDERABAD, India, Feb. 10, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2012, ended December 31, 2011.MONMOUTH JUNCTION, N.J., Feb. 10, 2012 /PRNewswire/ -- Insmed Incorporated, a biopharmaceutical company, today announced that the Company is proceeding with a phase 2 clinical trial of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease, as well as the previously planned European registration phase 3 clinical study of ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections.LONDON, February 10, 2012 /PRNewswire/ --Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces today the promotion of Tony Sedgwick PhD, FRCPath to the role of Chief Executive Officer from Chief Business Officer with immediate effect and the departure of Thomas Christély who has resigned as a Director of the Company for personal reasons but will ensure a smooth transition.CHENGDU, China, Feb. 10, 2012 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the research, development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced that the Company is invited to attend the 32nd Cowen's Healthcare Conference which is to take place from Monday March 5th through Wednesday March 7th at the Boston Marriott Copley Place Hotel.SOUTH SAN FRANCISCO, Calif. & BRUSSELS--(BUSINESS WIRE)--Feb 10, 2012 - Nodality, Inc. and UCB Pharma S.A. today announced a strategic collaboration utilizing Nodality's proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds.HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb 10, 2012 - Taro Pharmaceutical Industries Ltd. today provided unaudited financial results for the quarter and full year ended December 31, 2011.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 10, 2012 - Ironwood Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 5,250,000 shares of its Class A common stock at a price of $15.09 per share to the public. All of the shares are being offered by Ironwood.WASHINGTON--(BUSINESS WIRE)--Feb 10, 2012 - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars:MILFORD, Mass., Feb. 10, 2012 /PRNewswire/ -- SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported financial results for its 2012 fiscal first quarter ended December 31, 2011.TORONTO, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2011.Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM ESTTUSTIN, CA -- (MARKET WIRE) -- 02/09/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, its president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO and Investor Conference in New York on Tuesday, February 14, 2012 at 8:30 AM Eastern Standard Time (EST).BELLEVILLE, ON, Feb. 9, 2012 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it will discuss its financial results for the second quarter of its 2012 fiscal year.PRINCETON, N.J., Feb. 10, 2012 /PRNewswire/ -- Soligenix, Inc., a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.Geneva, Switzerland, February 10, 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading biopharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr. Bharatt Chowrira, CEO of Addex, will present at 9am EST on February 14, 2012, at the BIO CEO & Investor Conference in New York City.Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold marketTORONTO, Feb. 10, 2012 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the third quarter ended December 31, 2011.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 10, 2012 - Exelixis, Inc. today announced the pricing of its underwritten public offering of 11,000,000 shares of newly issued common stock at a price to the public of $5.50 per share.Oxford, UK – 10 February 2012: Oxford BioMedica, the leading gene-based biopharmaceutical company, today announces that Andrew Wood, Chief Financial Officer, has stepped down from the Board of Oxford BioMedica.?ANAHEIM, Calif., Feb. 10, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. announced today that executive management will present at the Leerink Swann Global Healthcare Conference to be held on February 15-16, 2012 in New York. Steve Cartt, Executive Vice President and Chief Business Officer, is scheduled to present an overview of the Company on Thursday, February 16, 2012 at 2:30 p.m. ET.Trondheim, Norway, February 10, 2012 / B3C newswire / - Vectron Biosolutions announced today that they have obtained strong results for manufacture of selected biosimilar proteins using their proprietary E. coli expression technology. The study was done side-by-side with other expression technologies and Vectron’s technology gave higher soluble and/or insoluble yields for seven out of 10 tested biosimilar proteins. The increase in yield was 2 to 25 times compared to the best conventional technology.Copenhagen, Denmark; February 10, 2012 – Genmab A/S announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment.NOVATO, Calif., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that its Chief Executive Officer, Christopher M. Starr, Ph.D., will present an overview of the Company at three investor conferences in February.PHILADELPHIA, Feb. 9, 2012 /PRNewswire-USNewswire/ -- The largest genetics study to date of type 2 diabetes (T2D) has identified new gene variants associated with risk for the common metabolic disease.PITTSBURGH, Feb. 9, 2012 /PRNewswire/ -- Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg.DUBLIN, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - Astex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one person abstaining that data in our partner Eisai's supplemental new Drug Application (sNDA) for Dacogen (decitabine) for Injection did not support a favorable benefit-risk profile for the treatment of acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.LONDON, Feb. 10, 2012 (GUARDIAN) - Pharmaceuticals companies are owed euros 12bn (pounds 10bn) for unpaid medicine bills in the eurozone - half of that in Spain - according to a senior executive, who said that the industry was counting on the help of the International Monetary Fund and the European Union to recover its debts. -
10 Feb ' 02:04
Feb 10, 2012 -
09 Feb ' 19:32
LEXINGTON, Mass., Feb. 9, 2012 (AP) -- Cubist Pharmaceuticals Inc. said Thursday that Hospira Inc. is challenging the patents supporting its antibiotic Cubicin, which brings in almost all of Cubist's revenue.PHILADELPHIA--(BUSINESS WIRE)--Feb 9, 2012 - Today, in the Philadelphia Court of Common Pleas, six attorneys from across the country filed what is believed to be the first birth defect case against EFFEXOR, a popular and common drug used in the treatment of depression.FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Feb 9, 2012 - In order to provide people with cancer and their caregivers state-of-the-art treatment information in patient-friendly language, the National Comprehensive Cancer Network (NCCN) has developed two new publications: a new release of the NCCN Guidelines for Patients™: Colon Cancer and an update to the NCCN Guidelines for Patients™: Prostate Cancer.WASHINGTON--(BUSINESS WIRE)--Feb 9, 2012 - The Lupus Foundation of America (LFA) seeks grant applications to advance the science and medicine of lupus and to help improve the quality of lives of all people affected by this disease.BOULDER, Colo.--(BUSINESS WIRE)--Feb 9, 2012 - Array BioPharma Inc. today announced that its President and Chief Scientific Officer, Kevin Koch, will speak at the Leerink Swann Healthcare Conference in New York.HAYWARD, Calif., February 09, 2012, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. , a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, will release its fourth quarter 2011 financial report before the market opens on Tuesday, February 21, 2012.GREENWOOD VILLAGE, Colo., Feb. 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced financial results for the year ended December 31, 2011, and offered a summary of the milestones during 2011.SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, February 15, 2012 at 8:00am Eastern Time (5:00am Pacific Time) during the Leerink Swann 2012 Global Healthcare Conference at the Waldorf Astoria Hotel in New York City.BRISBANE, Calif., Feb. 9, 2012 /PRNewswire/ -- InterMune, Inc. today announced that Jonathan A. Leff, M.D., has been appointed InterMune's Executive Vice President of Research and Development, effective February 27, 2012.ROCHESTER, N.Y., Feb. 9, 2012 /PRNewswire/ -- VirtualScopics, Inc., a leading provider of quantitative imaging for clinical trials, today announced that it has received notification from The Nasdaq Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement, and further, that it currently complies with all other applicable standards for continued listing.BRISBANE, Calif., Feb. 9, 2012 /PRNewswire/ -- InterMune, Inc. today announced results from operations for the fourth quarter and full year ended December 31, 2011.SAN FRANCISCO, Feb. 9, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. today announced that it will host a webcast and teleconference with management to discuss fourth quarter and full year 2011 financial results, as well as provide a general business overview, on Wednesday, February 22, 2012, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).RANCHO CORDOVA, Calif., Feb. 9, 2012 /PRNewswire/ -- ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, today reported results for the second quarter of fiscal 2012.BELLEVILLE, ON, Feb. 9, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it will discuss its financial results for the second quarter of its 2012 fiscal yearYORK, Pa., Feb. 9, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced financial results for the quarter ended December 31, 2011 (Second Quarter of Fiscal Year 2012).SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is offering to sell 6,800,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is the sole book-running manager of the offering, and Halozyme intends to grant them a thirty (30) day option to purchase up to an additional 1,020,000 shares of common stock.LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - Synageva BioPharma Corp., a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced encouraging safety and tolerability data as well as effects consistent with preclinical findings and known mechanism of action.VIENNA, Va.--(BUSINESS WIRE)--Feb 9, 2012 - CEL-SCI Corporation reports financial results for the fiscal quarter ended December 31, 2011.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases and Hydra Biosciences, Inc., a leader in the discovery and development of novel ion channels, today announced that they have entered into a collaboration to advance development of Zalicus' preclinical ion channel modulator product candidates for the treatment of pain.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - Exelixis, Inc. today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering.DUBLIN--(BUSINESS WIRE)--Feb 9, 2012 - Alkermes plc announced today that its corporate presentation will be webcast live at the Leerink Swann 2012 Global Healthcare Conference on Thursday, Feb. 16, 2012, at 3:00 p.m. EST (8:00 p.m. GMT) from the Waldorf=Astoria Hotel in New York City.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - Exelixis, Inc. today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering.PASADENA, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December 31, 2011.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2011, and company highlights. -
09 Feb ' 13:27
SILVER SPRING, Md., Feb. 9, 2012 - FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medicines when they are used together.SILVER SPRING, Md., Feb. 9, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.DUBLIN, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - Astex Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one person abstaining that data in our partner Eisai's supplemental new Drug Application (sNDA) for DACOGEN(decitabine) for Injection did not support a favorable benefit-risk profile for the treatment of acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc., a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive Officer and Chairman, will be the featured presenter at the upcoming Harvard Investors Group forum.SOUDERTON, Pa.--(BUSINESS WIRE)--Feb 9, 2012 - Almac is pleased to announce the doubling of analytical capacity at its 240,000 sq. ft. North American Headquarters.AMSTERDAM, Feb. 9,2012 /PRNewswire/ -- Leading events organiser UBM Conferences, a division of UBM Plc, today announced the addition of further speakers at the fifth annual PharmaSource Conference, being held from 21 to 23 February 2012 at the Hilton Munich City in Germany. TheSAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Ambit Biosciences today announced that Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib, at two upcoming investor conferences at the Waldorf Astoria in New York City.Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced its fourth quarter and 2011 full year results. Sales reached yet another all time high in the fourth quarter and profit margins improved significantly. Navamedic also made its debut in the generic pharmaceuticals market in the quarter.New York, February 9, 2012 — Alejandro Villageliu, a leading pharmaceutical marketing executive with over 12 years of experience in consulting, HCP marketing and sales strategy for pharmaceutical companies, has joined Heartbeat Ideas as Group Account Director.WALTHAM, MA - February 09, 2012 - Repligen Corporation (NASDAQ:RGEN) announced today that it will disclose preliminary financial results for the third quarter of fiscal year 2012 on Tuesday, February 21, 2012, before the market opens. The Company will host a conference call and webcast on the same day at 10 a.m. EST, to discuss the financial results and provide a quarterly corporate update.KVISTGAARD, Denmark, February 9, 2012 - Bavarian Nordic (NASDAQ OMX: BAVA) announced today that it will present at the 14th Annual BIO CEO & Investor Conference in New York on Tuesday, February 14, 2012?at 2:00 p.m. ET.MISSISSAUGA, ON, Feb. 9, 2012 - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its second quarter of fiscal 2012, ended December 31, 2011.BOSTON, Mass., February 9, 2012 – Acetylon Pharmaceuticals today announced that Celgene Corporation (NASDAQ: CELG) will invest a total of $15 million in Acetylon via the purchase of Series B-2 Preferred Stock. ?Mark Alles, Celgene’s Chief Commercial Officer will serve as a non-voting observer to the Acetylon Board of Directors.? Celgene does not receive rights or options to Acetylon technology under the terms of the equity purchase agreements.BETHESDA, Md., Feb 9 2012-- The National Institutes of Health has created a new website, NIH Clinical Research Trials and Youto help people learn more about clinical trials, why they matter, and how to participate. From the first cure of a solid tumor with chemotherapy to the use of nitroglycerin in response to heart attacks, clinical research trials -- or research studies involving people -- have played a vital role in improving health and quality of life for people around the globe. HORSHOLM, Denmark, Feb. 9, 2012 /PRNewswire/ -- William J. Polvino M.D president and CEO of Veloxis Pharmaceuticals A/S, will present at the 14th Annual BIO CEO & Investor Conference at 3 p.m. EST, Tuesday, Feb. 14, at The Waldorf-Astoria in New York.WEST LAFAYETTE, Ind. February 9, 2012 - A quick, interactive survey taken on an iPad could help pharmacists and patients better use their brief time together to catch and eliminate harmful drug side effects.NEW YORK--(BUSINESS WIRE)--Feb 9, 2012 - Alejandro Villageliu, a leading pharmaceutical marketing executive with over 12 years of experience in consulting, HCP marketing and sales strategy for pharmaceutical companies, has joined Heartbeat Ideas as Group Account Director.WASHINGTON, Feb. 9, 2012 /PRNewswire-USNewswire/ -- New 2012 Medicare Part D data released by the Centers for Medicare & Medicaid Services (CMS) show the growing popularity among Medicare Part D beneficiaries in choosing plans featuring lower cost preferred pharmacy network options.CORAL SPRINGS, Fla., Feb. 9, 2012 /PRNewswire/ -- Point-of-Care Partners (POCP)--a national healthcare information technology and strategy consulting firm--has just released a new white paper on prior authorization for medications, which is a trend to watch in 2012.HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb 9, 2012 - Acorda Therapeutics, Inc. today announced that Ron Cohen, M.D., President & CEO, will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 4:00 pm ET at the Walfdorf=Astoria Hotel in New York, NY.ST. LOUIS, Feb. 9, 2012 /PRNewswire/ -- Mobius Therapeutics, LLC, a St. Louis-based ophthalmic company, has received final approval from the U.S. Food and Drug Administration for the platform product, Mitosol®.HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb 9, 2012 - Acorda Therapeutics, Inc. today announced that it will host a conference call and live webcast to report its fourth quarter and full year 2011 financial results on Thursday, February 16 at 8:30 a.m. ET.SAN MATEO, Calif--(BUSINESS WIRE)--Feb 9, 2012 - A survey of 337 retirees on Medicare revealed that 62%1 of respondents are “somewhat” or “very” confident that Medicare will be there for the rest of their lives.DALLAS--(BUSINESS WIRE)--Feb 9, 2012 - Branham Law Group, LLP, a Dallas, Texas law firm, is investigating Pfizer for its recall of 14 lots of Lo/Ovral-28 tablet packs and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets.BETHLEHEM, Pa., Feb. 9, 2012 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and CHEMO, a multinational and pharmaceutical company with strong industrial capacities for APIs and Finished-Dosage-Forms (FDF), have formed a partnership to offer complete contract product development and commercial manufacturing of hormone-eluting devices.LAKE JACKSON, Texas--(BUSINESS WIRE)--Feb 9, 2012 - Congressman and 2012 Republican Presidential candidate Ron Paul issued the following statement regarding the Obama Administration's announcement that religious organizations must pay for contraception and sterilization under the national health care law:INDIANAPOLIS, Feb. 9, 2012 /PRNewswire/ -- Get your canvases, paintbrushes and cameras ready — the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) today announced the launch of the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.SAN DIEGO--(BUSINESS WIRE)--Feb 9, 2012 - Ligand Pharmaceuticals Incorporated announced today that John Higgins, President and Chief Executive Officer of Ligand will present at the BIO CEO and Investor Conference on Monday, February 13, 2012 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time).PHILADELPHIA, Feb. 9, 2012 /PRNewswire-USNewswire/ -- The largest genetics study to date of type 2 diabetes (T2D) has identified new gene variants associated with risk for the common metabolic disease.ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb 9, 2012 - New analysis shows that health care spending in the U.S. in 2011 grew at one of the slowest rates in 50 years according to the February Health Sector Economic Indicators briefs released today by Altarum Institute's Center for Sustainable Health Spending.PARIS--(BUSINESS WIRE)--Feb 9, 2012 -Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy for severe neurological diseases, today announced that it has raised €8 million in two tranches in October and December 2011. This fundraising follows a €2.5 million round closed in June 2011.SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen Therapeutics, Inc. today announced that management will be presenting at two upcoming investor conferences.EAST HANOVER, N.J., Feb. 9, 2012 /PRNewswire/ -- Unity Management Group, Inc. announced today its wholly owned subsidiary Metropolitan Computing Corporation (or MCC) has completed a maintenance contract on a Presster Tablet Presses at the University of Basel's Department of Pharmaceutical Science.NEW YORK--(BUSINESS WIRE)--Feb 9, 2012 - Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President and CEO, Gary S. Jacob, Ph.D, will present at the 14th Annual BIO CEO & Investor Conference.NEW YORK, Feb. 9, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Columbia Laboratories Inc. -
09 Feb ' 07:14
Feb 9, 2012NEW DELHI, Feb. 9, 2012 (AP) -- Efforts by India and the European Union to strengthen trade are threatening India's ability to deliver life-saving medicines to the world's poorest, analysts say as the two sides resume protracted negotiations on a free-trade pact.NEW YORK, Feb. 9, 2012 /PRNewswire/ -- Just weeks after winning preliminary approval of a 99 million dollar settlement on behalf of Novartis Pharmaceuticals Sales Representatives, Attorneys from Sanford Wittels & Heisler, LLP today filed a class action complaint in the U.S. District Court for the Southern District of New York on behalf of four former Sales Representatives and other similarly-situated employees at LEO Pharma Inc.HAYWARD, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - Impax Laboratories, Inc. today provided an update on the status of its resolution of the previously disclosed warning letter issued by the FDA covering its Hayward manufacturing facility.EVERETT, Wash.--(BUSINESS WIRE)--Feb 9, 2012 - SNBL USA, contract research organization and the leader in NHP experience and expertise, today announced it is on track with the implementation and launch of Instem's Provantis preclinical software solution suite in November 2012.FREMONT, Calif., Feb. 9, 2012 /PRNewswire/ -- WaferGen Biosystems, Inc., an emerging genomic analysis company, today announced that the company will deliver its corporate presentation at the 14th Annual BIO CEO & Investor Conference, February 13 and 14, 2012 at the Waldorf Astoria, New York, NY.LONDON, Feb. 9, 2012 /PRNewswire-USNewswire/ -- WomanCare Global announced today that mifepristone has been added to their reproductive healthcare portfolio.YARDLEY, Pa.--(BUSINESS WIRE)--Feb 9, 2012 - The first patients have been successfully enrolled in a phase III study involving the intranasal delivery of sumatriptan powder using the OptiNose bi-directional technology.LOS ANGELES--(BUSINESS WIRE)--Feb 9, 2012 - Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 3:30 p.m. EST, Thursday, February 16, at the Leerink Swann 2012 Global Healthcare Conference.STEVENAGE, England, February 9, 2012 /PRNewswire/ --Stevenage Bioscience Catalyst (SBC), the UK's first open innovation bioscience campus, is pleased to announce that it is now open for business.WALTHAM, Mass., Feb. 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that scientists at Roswell Park Cancer Institute have demonstrated that entinostat, Syndax's novel, oral small molecule inhibitor of class I histone deacetylases, has novel immunomodulatory properties that contribute to the enhanced activity of cancer immunotherapies in models of renal and prostate cancer.PRINCETON, N.J.--(BUSINESS WIRE)--Feb 9, 2012 - Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that Tom Moore, Chairman & CEO of Advaxis, will present a corporate overview of the Company at the 14th Annual BIO CEO & Investor Conference at the Waldorf=Astoria in New York City on February 13, 2012 at 10:30am EST in the Duke of Windsor room.NEEDHAM, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - Celldex Therapeutics, Inc. today announced that Thomas Davis, M.D., Senior Vice President and Chief Medical Officer of Celldex Therapeutics, Inc., will participate with other industry executives in a therapeutic workshop panel discussion titled Drugs Need Friends Too – Companion Diagnostics and Drug Development.WOBURN, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - ArQule, Inc. today announced that the Company will present at the Leerink Swann 2012 Global Healthcare Conference on February 16, 2012 at 11:00 a.m..BARCELONA, Feb. 9, 2012.- Bayer and Almirall announced today an agreement to co-promote Rivaroxaban (Xarelto) in Spain beginning in the coming months. Rivaroxaban, an oral anticoagulant developed by Bayer, is the only new oral anticoagulant approved in three indications across Europe.RALEIGH, N.C., Feb. 9, 2012 (NEWS & OBSERVER) - Aldagen, a Durham biotechnology company whose attempts to go public didn't pan out, has been sold in a deal valued at more than $40 million.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics.Osaka, Japan, February 09, 2012—Takeda Pharmaceutical Company Limited (“Takeda”) announced today the establishment of the Takeda Shanghai Development Center (“TSDC”) within the Shanghai-based Takeda (China) Holdings Co., Ltd. (“TCH”), which is a wholly owned subsidiary of Takeda.WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - BioMolded Products, LLC, today announced the opening of its new product design and manufacturing facility specializing in medical-grade blow molded plastic parts for the biopharmaceutical and life science industries.WASHINGTON, Feb. 8, 2012 (CANADAIAN PRESS BROADCAST WIRE) - The watchdog agency for the accounting industry said Wednesday that it has fined big firm Ernst & Young $2 million for alleged lapses in three audits of a pharmaceutical company.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced that Duncan Higgons, chief operating officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 11AM EST at the Waldorf Astoria Hotel in New York City.BOSTON--(BUSINESS WIRE)--Feb 9, 2012 - Acetylon Pharmaceuticals today announced that Celgene Corporation will invest a total of $15 million in Acetylon via the purchase of Series B-2 Preferred Stock.LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb 9, 2012 - BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.MISSISSAUGA, ON, Feb. 9, 2012 /PRNewswire/ - YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its second quarter of fiscal 2012, ended December 31, 2011.DUBLIN, Ireland, February 9, 2012 /PRNewswire/ --Shire plc, the global specialty biopharmaceutical company, announces results for the year to December 31, 2011.Leiden, The Netherlands, February 9, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has redeemed the second tranche of its €8.4 million convertible bond. A total of 8,351,146 shares were issued to the bondholders under the terms and conditions of the bond, serving as a pre-installment for the March 12, 2012 redemption and interest paymentST. LOUIS, Feb. 9, 2012 /PRNewswire/ -- K-V Pharmaceutical Company today reported updated performance metrics for Makena.CRANBURY, N.J., Feb. 9, 2012 /PRNewswire/ -- Palatin Technologies, Inc. announced that it will be presenting at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 8:30 a.m. ET.MENLO PARK, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced the expansion of its executive management team with the appointments of Nima Farzan as Executive Vice President and Chief Operating Officer, Thomas P. Monath, M.D. as Chief Technology Officer, and Jonathan F. Smith, Ph.D. as Executive Vice President and Chief Scientific Officer.February 9, 2012, Bangalore: Hikal Limited, a leading manufacturer of active ingredients, intermediates and regulated starting materials successfully completed its 3rd US FDA audit at its manufacturing facility located at Jigani, Bangalore.Basel, Switzerland, February 9, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) today presented solid financial results for the full-year 2011 with a year-end cash position of CHF?197.1?million and a lower than expected operating loss of CHF?57.3?million. In 2011, sales of Basilea's hand eczema drug Toctino (alitretinoin) increased to CHF?31.0?million in line with the company's guidance, representing a year-on-year volume growth of 24?percent.Oslo, Norway, 9 February 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its results for the fourth quarter and full year 2011.HYDERABAD, India and NEW ORLEANS, Feb. 9, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will launch a mobile app version of its GuarD project management system at the Informex USA 2012 conference.PITTSBURGH, Feb. 9, 2012 /PRNewswire/ -- Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg.MISSISSAUGA, ON, Feb. 9, 2012 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its second quarter of fiscal 2012, ended December 31, 2011.QUEBEC CITY, Feb. 9, 2012 /CNW/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Pierre Labbé, Vice-president and Chief Financial Officer of Medicago, will be presenting at the 14th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf Astoria in New York City from on February 13th and 14th, 2012. Mr. Labbé is scheduled to present on February 13th, 2012 at 11:30 am ET. -
08 Feb ' 19:52
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Ironwood Pharmaceuticals, Inc. announced that it was informed this evening that the U.S. Food and Drug Administration (FDA) will not schedule an advisory committee meeting in connection with the its review of the New Drug Application (NDA) for linaclotide proposed for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that Gregory Schafer, the company's chief financial officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference next week in New York City.HAYWARD, Calif.--(BUSINESS WIRE)--Feb 8, 2012 - Aradigm Corporation today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 14th Annual BIO CEO & Investor Conference 2012 on Monday, February 13, 2012, at 2:30 p.m. ET.DUBLIN, Ohio--(BUSINESS WIRE)--Feb 8, 2012 - Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has opened a business and commercial development office in Andover, MA, just outside of Boston.MISSISSAUGA, Ontario, Feb. 8, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, February 27, 2012 at 10:00 a.m. ET (7:00 a.m. PT) to discuss results for the 2011 fourth quarter and full year.SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. announced today that Jack Lief, Arena's President and Chief Executive Officer, and Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, are scheduled to present a corporate overview and update at two upcoming investor conferences at the Waldorf=Astoria in New York City.NEW YORK--(BUSINESS WIRE)--Feb 8, 2012 - Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced that it has engaged The Trout Group LLC a leading investor relations and strategic advisory firm.SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb 8, 2012 - Relypsa, Inc. today announced the hiring of Lance Berman, M.D. as its Senior Vice President of Commercial Strategy & Medical Affairs.SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- BioMed Realty Trust, Inc, a real estate investment trust focused on Providing Real Estate to the Life Science Industry, today announced financial results for the fourth quarter and full-year ended December 31, 2011.DANBURY, Conn., Feb. 8, 2012 /PRNewswire/ -- Biodel Inc. today reported financial results for the first quarter ended December 31, 2011.CRANBURY, N.J., Feb. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. will announce its second quarter, fiscal year 2012 financial results on Wednesday, February 15, 2012 before the open of the U.S. financial markets.BELLEVILLE, ON, Feb. 8, 2012 /PRNewswire/ - Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the second quarter of its 2012 fiscal year (ended December 31, 2011).EAST BRUNSWICK, N.J., Feb. 8, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012 at 2:00 PM Eastern Time.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced presentations at several upcoming investment conferences.WASHINGTON--(BUSINESS WIRE)--Feb 8, 2012 - Today, the Lupus Foundation of America (LFA) announced new research grants awarded to fund critical areas of research where gaps exist in the understanding and knowledge of lupus including: pediatric lupus, cutaneous (skin) lupus, mid-to-late stage translational research, adult stem cells, and neuropsychiatric lupus, which affects the brain and nervous system.LOS ANGELES--(BUSINESS WIRE)--Feb 8, 2012 - KYTHERA Biopharmaceuticals, Inc., a privately held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, announced today that Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the Leerink Swann 2012 Global Healthcare Conference in New York City.SEATTLE, Feb. 8, 2012 /PRNewswire/ -- Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference taking place in New York City next week.NOKOMIS, Fla.--(BUSINESS WIRE)--Feb 8, 2012 - As Rainbow BioSciences, the biotech division of Rainbow Coral Corp., continues to vet investment banks to assist with its capital raise, investors remain optimistic on the returns that new biotech firms can bring. A recent report indicates that venture capital investments in biotech increased by 22 percent to $4.7 billion last year.BERLIN, Feb. 8, 2012 /PRNewswire/ -- caprotec bioanalytics GmbH announced today the issuance of patents in the US, Japan, Canada, Australia and Israel related to methods and composition of matter of its proprietary Capture Compound Mass Spectrometry (CCMS) technology.RESTON, Va.--(BUSINESS WIRE)--Feb 8, 2012 - MAXIMUS announced today that it has signed a new contract with the Government of Ontario's Ministry of Health and Long-Term Care to provide administrative services for the Ontario Drug Benefit (ODB) Program.BEDMINSTER, N.J.--(BUSINESS WIRE)--Feb 8, 2012 - NPS Pharmaceuticals, Inc. announced today that it will report its 2011 financial results on Wednesday, February 15, 2012 at approximately 4:30 p.m. ET.VALENCIA, Calif.--(BUSINESS WIRE)--Feb 8, 2012 - MannKind Corporation today announced the completion of an underwritten public offering of 35,937,500 units, including 4,687,500 units sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters (with each unit consisting of one share of its common stock and a warrant to purchase 0.6 of a share of its common stock).DUBLIN--(BUSINESS WIRE)--Feb 8, 2012 - Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Ironwood Pharmaceuticals, Inc. announced today that it has commenced an underwritten public offering of 5,250,000 shares of its Class A common stock. All of the shares are being offered by Ironwood.TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb 8, 2012 - EpiCept Corporation today announced that Jack Talley, President and Chief Executive Officer, will be presenting at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 3:00 PM Eastern time at The Waldorf=Astoria in New York City. Mr. Talley will present a company overview.NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office relating to its new formulation of Acetadote(acetylcysteine) Injection, which is used to treat acetaminophen poisoning.PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 8, 2012 - Anacor Pharmaceuticals, today announced the sale of 3.25 million shares of its common stock for gross proceeds of $21,450,000 pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner.WESTON, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Biogen Idec Inc. announced today that its presentation at the Leerink Swann Global Healthcare Conference will be webcast live on Wednesday, February 15, 2012 at 8:30 a.m. ET. -
08 Feb ' 13:38
WESTON, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Biogen Idec Inc. announced today that its presentation at the Leerink Swann Global Healthcare Conference will be webcast live on Wednesday, February 15, 2012 at 8:30 a.m. ET.BOULDER, Colo.--(BUSINESS WIRE)--Feb 8, 2012 - Array BioPharma Inc. announced today that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 8, 2012 - Exelixis, Inc. today reported financial results for the fourth quarter and year ended December 31, 2011.SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb 8, 2012 - Affymetrix, Inc., today reported its operating results for the fourth quarter and fiscal year ended December 31, 2011.SAN DIEGO--(BUSINESS WIRE)--Feb 8, 2012 - Illumina, Inc. today announced its financial results for the fourth quarter and fiscal year of 2011.NEW YORK, Feb. 8, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 14th Annual BIO CEO and Investor Conference, which will be held at the Waldorf=Astoria Hotel in New York City.THE WOODLANDS, Texas--(BUSINESS WIRE)--Feb 8, 2012 - Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 11:30 a.m. EST.BEND, Ore., February 08, 2012, 2012 /PRNewswire/ -- Bend Research Inc. (www.bendresearch.com), a leading independent drug-formulation development and manufacturing company, announced today that it has entered into a licensing agreement with Eli Lilly and Company.BILLERICA, Mass., Feb. 8, 2012 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of the new BD Mosaic Mesenchymal Stem Cell Serum-Free (hMSC SF), a complete cell culture environment for human mesenchymal stem cells (hMSCs) derived from bone marrow.PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 8, 2012 - Affymax, Inc. today announced that John Orwin, the company's chief executive officer, will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 3:00 p.m. Eastern Time in New York City.PHOENIX, Feb. 8, 2012 /PRNewswire-iReach/ -- The Apothecary Shops Specialty Pharmacies has received distribution rights from pharmaceutical manufacturer Pfizer for its new drug Inlyta(axitinib), and will begin to provide this new drug to patients immediately.SHANGHAI, Feb. 8, 2012 /PRNewswire-Asia / -- WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2011 after the New York Stock Exchange closes on Thursday, March 8, 2012 (which will be Friday morning, March 9, 2012 Shanghai time).OXFORD, England, February 8, 2012 /PRNewswire/ --Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of Energy Strategy Reviews, a new quarterly, peer-reviewed journal focusing on energy strategy, planning and decision making.NEW YORK--(BUSINESS WIRE)--Feb 8, 2012 - Bristol-Myers Squibb Company will present at the Leerink Swann 2012 Global Healthcare Conference Wednesday, February 15, 2012, in New York.Mulhouse, France and Cambridge, Massachusetts, USA, January 25 2012 - Rhenovia Pharma SAS, a biotechnology company specializing in biosimulation applied to the discovery of new medications to treat brain diseases such as Alzheimer’s, today announces its first international subsidiary, Rhenovia Inc, incorporated in DelawareWHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 8, 2012 - Merck, known as MSD outside the United States and Canada, announced today that Thomas E. Shenk, Ph.D., has decided to retire from its board of directors, effective today.ROTTERDAM, The Netherlands and GHENT, Belgium, February 8, 2012 /PRNewswire/ --arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development.ROCKVILLE, Md., Feb. 8, 2012 /PRNewswire/ -- Neuralstem, Inc. announces that President and CEO Richard Garr will present at the 14th Annual BIO CEO & Investor Conference 2012 in New York City on Monday, February 13, at 3:00 p.m. EST.PALO ALTO, Calif., Feb. 8, 2012 /PRNewswire/ -- Telik, Inc. today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 14 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite.FORT LAUDERDALE, Fla., Feb. 8, 2012 /PRNewswire/ -- Attendees at the 2012 Pharmaceutical Care Management Association (PCMA)'s Managed Markets Educational Forum yesterday heard Prime Therapeutics President and CEO Eric Elliott speak about the dynamic changes facing pharmaceutical companies and pharmacy benefit managers entering the post-reform health care space, including the high increase in the number of chronically ill, soaring costs from the rapid rise of specialty medications and the rising importance of clinically integrated care.NEW YORK, Feb. 8, 2012 /PRNewswire/ -- At a late January ceremony at New York City Fire Department headquarters in downtown Brooklyn, Howard P. Milstein, chair of the New York Blood Center (NYBC), joined Fire Commissioner Salvatore J. Cassano and Christopher D. Hillyer, M.D., President and CEO of NYBC, to add the names of six 2011 FDNY bone marrow donors to NYBC's "Honor Roll of Life."PARSIPPANY, N.J., February 8 - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), representing the largest assembly of creative talent in the world of healthcare communications, today announced the addition of Iyiola Obayomi as senior director, consulting at Ogilvy Healthworld’s New York City office.WILMINGTON, Mass., Feb. 8, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc. (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Leerink Swann 2012 Global Healthcare Conference.?Lille (France), Cambridge (Massachusetts, United States), February 8th, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the results of long-term animal toxicology studies involving up to two years of treatment. At the highest doses tested, GFT505 has no major adverse effect relevant to humans. In particular, none of the adverse effects previously observed in similar studies with the different classes of oral anti-diabetes drugs has been observed.KIRKLAND, QC, Feb. 8, 2012 /CNW Telbec/ - John Helou has been named President of Pfizer Canada Inc., Canada's largest pharmaceutical company, effective January 31, 2012.NEW HAVEN, Conn., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael Kishbauch, President and Chief Executive Officer of Achillion, will provide a corporate update at the following upcoming investor conferences:Louisville, Colo. - Feb. 8, 2012 - GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to be conducted at the National Cancer Institute (NCI) to investigate the safety and tolerability of GI-6301, a new Tarmogen product, for patients with metastatic cancers containing brachyury protein. Brachyury is over-expressed in a variety of important tumor types including breast, colon, lung and prostate cancers.NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. announced today that it will release 2011 year-end financial results after the market closes on Wednesday, February 29, 2012.TORONTO, Feb. 8, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2011. All dollar amounts referenced herein are in United States dollars unless otherwise noted.Overland Park, KS, February 8, 2012– Vince and Associates Clinical Research, the premier provider of innovative early clinical research services to the global biopharmaceutical industry, announces the certification of their pharmacy clean room in compliance with United States Pharmacopeia USP guidelines. This certification enables Vince and Associates Clinical Research to prepare intravenous and other preparations to the highest clinical research standards.Oxford and Newcastle, UK, 8 February 2012 - Drug discovery and development company e-Therapeutics plc (AIM: ETX) announces that its CFO, Dr Daniel Elger, will present an overview of the Company’s strategy, platform and clinical development programmes at the 14th Annual BIO CEO & Investor Conference in New York on Monday 13 February at 2.00 pm EST (1900 BST).NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. announced today that it will release 2011 year-end financial results after the market closes on Wednesday, February 29, 2012.ZURICH, SWITZERLAND and MORRISVILLE, N.C. (Business Wire) February 8, 2012 -- Clinipace Worldwide, a global digital contract research organization (dCRO) that has pioneered technology-amplified contract research services, announced today the appointment of Jürgen Frisch, MD, to Chief Medical Officer of European Operations.?NEW YORK, Feb. 8, 2012 --?Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 14th Annual BIO CEO and Investor Conference, which will be held at the Waldorf=Astoria Hotel in New York City. Mr. Bentsur's presentation is scheduled to take place on Tuesday, February 14, 2012 at 9:00 a.m. ET.?SARATOGA, Calif. and MEQUON, Wis., Feb. 8, 2012 /CNW/ - The Myelin Repair Foundation (MRF) and ENDECE Neural, LLC have formed a partnership to expedite the advancement of myelin regeneration drug candidates for Multiple Sclerosis (MS) patients through pre-clinical studies and into Phase I clinical studies. -
08 Feb ' 08:37
SILVER SPRING, Md., Feb. 8, 2012 - FDA notified the public that the use of stomach acid drugs known as proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea (CDAD). A diagnosis of CDAD should be considered for patients taking PPIs who develop diarrhea that does not improve. The FDA is working with manufacturers to include information about the increased risk of CDAD with use of PPIs in the drug labels.RALEIGH, N.C., Feb. 8, 2012 (NEWS & OBSERVER) - GlaxoSmithKline's plans for reconfiguring its research-and-development efforts aim to boost cost-effectiveness without reducing the number of scientists in Research Triangle Park or elsewhere, said a company spokeswoman.BASEL, Switzerland, February 7, 2012 - The Journal of the American Medical Association (JAMA) published a study today that shows Bexsero induced a robust immune response against meningococcal B disease in the vast majority of infants vaccinated.THOUSAND OAKS, Calif., February 08, 2012, 2012 /PRNewswire/ -- Amgen will discuss the data from the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today's meeting of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC).Vancouver, BC — Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the commencement of patient enrollment in its Phase 1 clinical trial for TKM-Ebola.ALISO VIEJO, Calif., Feb. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the results of the study entitled "Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study" have been published in the February edition of the journal Pain Medicine.ATLANTA--(BUSINESS WIRE)--Feb 8, 2012 - The first class-wide risk evaluation and mitigation strategies (REMS) program for the transmucosal immediate-release fentanyl (TIRF) class of medications was approved in December by the Food and Drug Administration (FDA) and will be administered by RelayHealth and McKesson Specialty Health.LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb 8, 2012 - BioSante Pharmaceuticals, Inc., announced today that the company has entered into a privately-negotiated securities exchange agreement with a holder of BioSante's 3.125% convertible senior notes due May 1, 2013.CARY, N.C.--(BUSINESS WIRE)--Feb 8, 2012 - Biologics, Inc., an integrated oncology services company has been selected as a Limited Distribution Network (LDN) partner for Pfizer's Inlyta which was approved by the FDA on January 27, 2012.BUDAPEST, Hungary--(BUSINESS WIRE)--Feb 8, 2012 - World leader in fertility treatments, Ferring Pharmaceuticals, announced today at the 2012 Updates in Infertility Treatment (UIT) meeting that the company will initiate a new educational initiative with the International Federation of Fertility Societies (IFFS) and publishing group Elsevier to support a series of educational programmes and meetings.HUDDINGE, Sweden, February 8, 2012 /PRNewswire/ --Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.WASHINGTON--(BUSINESS WIRE)--Feb 8, 2012 - To help reduce the increasing number of preterm births in America and ensure more babies are born healthy, HHS Secretary Kathleen Sebelius announced more than $40 million in grants to test ways to reverse that trend, as well as a public campaign to reduce early elective deliveries.MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- ChemoCentryx, Inc. announced today the pricing of its initial public offering of 4,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.WAYNE, Pa.--(BUSINESS WIRE)--Feb 8, 2012 - Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2011 prior to market open on Wednesday, February 29, 2012.OVERLAND PARK, Kan.--(BUSINESS WIRE)--Feb 8, 2012 - Vince & Associates Clinical Research, the premier provider of innovative early clinical research services to the global biopharmaceutical industry, announces the certification of their pharmacy clean room in compliance with United States Pharmacopeia USP guidelines.WILMINGTON, Del.--(BUSINESS WIRE)--Feb 8, 2012 - AstraZeneca announced today that it broadened the income eligibility for its AZ&Me Prescription Savings programs to enable more people to qualify for free medicines.BOTHELL, Wash.--(BUSINESS WIRE)--Feb 8, 2012 - Seattle Genetics, Inc. announced today that management will present at the following upcoming investor conference.SUINING, China, Feb. 8, 2012/PRNewswire-Asia/ -- China Health Resource, Inc., announced today its plan to launch an aggressive Investors and Public Awareness Campaign throughout 2012.CALGARY, Feb. 8, 2012 /PRNewswire/ - Resverlogix Corp. is pleased to announce that Donald McCaffrey, President & Chief Executive Officer of Resverlogix will be presenting at The 14th Annual BIO CEO & Investor Conference on February 13, 2012 at 1:30 PM (EST) at the Waldorf Astoria, New York City.LOS ANGELES--(BUSINESS WIRE)--Feb 8, 2012 - DRX, a leading provider of healthcare comparison tools, technology and data, today announced the launch of the Company's iPad Mobile Field Enrollment application, a mobile enrollment solution for in-field Medicare sales agents.OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--Feb 8, 2012 - Drug discovery and development company e-Therapeutics plc announces that its CFO, Dr Daniel Elger, will present an overview of the Company's strategy, platform and clinical development programmes at the 14th Annual BIO CEO & Investor Conference in New York on Monday 13 February at 2.00 pm EST (1900 BST).BOSTON, Feb. 8, 2012 /PRNewswire/ -- PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the expansion of its global Clinical Logistics Services.ORLANDO, Fla.--(BUSINESS WIRE)--Feb 8, 2012 - PatientPoint, a provider of care coordination and patient engagement management solutions, today announced a strategic partnership with ACME MSO to provide automated care coordination services for its Clinical Value Network (CVN) of providers.ZURICH & MORRISVILLE, N.C.--(BUSINESS WIRE)--Feb 8, 2012 - Clinipace Worldwide, a global digital contract research organization (dCRO) that has pioneered technology-amplified contract research services, announced today the appointment of Jürgen Frisch, MD, to Chief Medical Officer of European Operations.PARSIPPANY, N.J., Feb. 8, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has reached a settlement with Janssen Pharmaceuticals, Inc. (formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc.) on outstanding patent litigation related to Watson's generic version of Janssen's Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets.BERWYN, Pa.--(BUSINESS WIRE)--Feb 8, 2012 - Formula Pharmaceuticals, a privately-held oncology drug development company, today announced the appointment of Wolfgang Oster, MD PhD as Chairman of the Board of Directors.FORT COLLINS, Colo. & ROCKVILLE, Md.--(BUSINESS WIRE)--Feb 8, 2012 - Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.HUDDINGE, Sweden--(BUSINESS WIRE)--Feb 8, 2012 - Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.Feb. 8, 2012 (AP) - Students at Shippensburg University in Pennsylvania can get the "morning-after" pill by sliding $25 into a vending machine, an idea that has drawn the attention of federal regulators and raised questions about how accessible emergency contraception should be.SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Ambit Biosciences today announced the appointment of Athena Countouriotis, M.D., as chief medical officer.SCHAUMBURG, Ill.--(BUSINESS WIRE)--Feb 8, 2012 - APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States.NEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Feb 8, 2012 - Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.WASHINGTON, Feb. 8, 2012 /PRNewswire-USNewswire/ -- The Synthetic Biology Project at the Woodrow Wilson Center is launching a new web-based Synthetic Biology Scorecard, designed to track federal and non-federal efforts to improve the governance of synthetic biology research and development so risks are minimized and broad social and economic benefits can be realized.PARIS & NEW YORK--(BUSINESS WIRE)--Feb 8, 2012 - Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix (clopidogrel bisulfate) patent infringement case against Apotex.LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Synta Pharmaceuticals Corp. today announced that it will release its fourth-quarter and year-end 2011 financial results before the market opens on Wednesday, February 22, 2012. -
07 Feb ' 21:57
Feb 8, 2012 -
07 Feb ' 17:41
EXTON, Pa., Feb. 7, 2012 /PRNewswire/ -- ViroPharma Incorporated today announced the U.S Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities.SAN DIEGO--(BUSINESS WIRE)--Feb 7, 2012 - Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, today announced that its Board of Directors thoroughly reviewed Roche's unsolicited tender offer with the assistance of its financial and legal advisors and unanimously determined that the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina's stockholders.SEATTLE, Feb. 7, 2012 /PRNewswire/ -- Omeros Corporation today announced that recent positive clinical developments have allowed it to revise the planned analysis for its ongoing Phase 3 clinical trial evaluating OMS302, which Omeros believes expands opportunities for the product's clinical and regulatory success.WALTHAM, Mass.--(BUSINESS WIRE)--Feb 7, 2012 - Repligen Corporation announced today that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 2 p.m. EST at the Waldorf Astoria in New York City.TEL AVIV, Israel--(BUSINESS WIRE)--Feb 7, 2012 - Compugen Ltd. today reported financial results for the fourth quarter and year ended December 31, 2011.THE WOODLANDS, Texas, Feb. 7, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the 2012 BIO CEO & Investor Conference in New York on Tuesday, February 14, 2012 at 10:00 a.m. Eastern Time.QUÉBEC CITY, Feb. 7, 2012 /PRNewswire/ - Aeterna Zentaris Inc. today announced that Paul Blake, MD, the Company's Senior Vice President and Chief of Medical Affairs, will be presenting a Company overview at the BIO CEO Investor Conference on Tuesday, February 14, 2012, at 3:30 pm (Eastern), in the Duke of Windsor Room of the Waldorf Astoria Hotel in New York City.WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Feb 7, 2012 - Bioanalytical Systems, Inc. will release financial results for the fiscal 2012 first quarter ended December 31, 2011 at approximately 7:30 a.m. EST on Friday, February 10, 2012.VALENCIA, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - MannKind Corporation, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.ALLEGAN, Mich., Feb. 7, 2012 /PRNewswire/ -- Perrigo Company today announced results for its second quarter and six months ended December 31, 2011.ST. LOUIS, Feb. 7, 2012 /PRNewswire/ -- Express Scripts, one of the largest pharmacy benefit management companies in North America, announced today its intention to release its fourth quarter earnings on Wednesday, February 22, 2012 after the market closes and will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 23, 2012, at 9:00 a.m. Eastern Time (8:00 a.m. Central Time).SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 11:00 a.m. Eastern time, in the Park South Salon at the Waldorf=Astoria Hotel in New York.ALBANY, N.Y., Feb. 7, 2012 /PRNewswire/ -- AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2011.BOTHELL, WA and VANCOUVER, BC, Feb. 7, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. announced today that Scott Cormack, Chief Executive Officer, will provide a corporate presentation at the following investor conferences:LAKE FOREST, Ill., Feb. 7, 2012 /PRNewswire/ -- Akorn, Inc. will host a conference call on Tuesday, March 6, 2012, to discuss fourth quarter and year-end 2011 results followed by a Q&A session.WASHINGTON, Feb. 7, 2012 /PRNewswire-USNewswire/ -- As the war on HIV/AIDS begins its fourth decade, medical researchers, pharmaceutical manufacturers, patient advocates and government regulators face a new and unexpected scientific challenge: how to demonstrate the safety and efficacy of promising new antiretroviral drugs when the two traditional study designs – the superiority trial and the non-inferiority trial – are no longer useful in showing improvements in both "treatment experienced" patients and those who have never received drug therapy (treatment-naive patients).SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- BIOCOM, the trade organization representing Southern California's life sciences industry, has released its first regional economic impact report showing conclusively that Southern California's life sciences cluster is one of the most vibrant, multi-faceted and innovative in the world.LA JOLLA, Calif. and IPSWICH, Mass., Feb. 7, 2012 /PRNewswire/ --Synthetic Genomics, Inc. (SGI), a privately held company commercializing and developing genomic-driven solutions to solve a variety of global needs, and New England Biolabs, Inc. (NEB), today jointly announced that they have entered into a non-exclusive licensing agreement whereby NEB will commercialize the Gibson Assembly Master Mix.SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced the publication in Molecular Therapy of data validating the mechanisms by which its lead product, JX-594, selectively targets and kills a broad range of cancer cells.INCLINE VILLAGE, Nev., Feb. 7, 2012 /PRNewswire/ -- PDL BioPharma, Inc. today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 1:00 p.m. ET in New York City.DUBLIN, Ohio--(BUSINESS WIRE)--Feb 7, 2012 - Navidea Biopharmaceuticals, Inc. today announced that Dr. Mark Pykett, President and Chief Executive Officer, will participate at the 14th Annual BIO CEO & Investor Conference, hosted by the Biotechnology Industry Organization (BIO), on February 13-14 at the Waldorf Astoria in New York City.POINT RICHMOND, Calif., Feb. 7, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at two upcoming investor conferences.GAITHERSBURG, Md., Feb. 7, 2012 /PRNewswire/ -- GenVec, Inc., a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines, today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a company overview highlighting recent developments at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 11:00 a.m. EST at the Waldorf Astoria Hotel in New York City.SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Applied Proteomics Inc. (API), powering the proteome to transform diagnostics, announced today the appointment of veteran diagnostic developer, Peter Klemm, Ph.D., as chief executive officer.WASHINGTON, Feb. 7, 2012 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani responded to new efforts unveiled today by the Administration to combat Alzheimer's Disease:LOS ANGLES--(BUSINESS WIRE)--Feb 7, 2012 - ImmunoCellular Therapeutics issued the following Letter to Shareholders today:DURHAM, N.C., Feb. 7, 2012 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, mourns the passing of its founder, James F. White, Ph.D. on February 3rd, after a lengthy illness.WASHINGTON, Feb. 7, 2012 /PRNewswire-USNewswire/ -- Congressman Chaka Fattah (D-PA), the leading Democratic appropriator for scientific research as Ranking Member on the House Appropriations Subcommittee on Commerce, Justice, Science, and a leader on neuroscience, issues this statement on the Obama Administration's plan to increase Alzheimer's disease research spending:EAST BRUNSWICK, N.J., Feb. 7, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. announced today that the Company's fourth quarter and year-end 2011 financial results will be released prior to the open of the market on Monday, February 27, 2012.LONG BEACH, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced it will report financial results for its fourth quarter and year ended December 31, 2011 after market close on Thursday, March 8, followed by an investor conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).SAN DIEGO--(BUSINESS WIRE)--Feb 7, 2012 - Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2011, and reviewed business highlights of the fourth quarter of 2011 and early 2012.LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 7, 2012 - AMAG Pharmaceuticals, Inc. today announced the appointment of Rajiv De Silva and Gino Santini to its board of directors, effective immediately.SAN DIEGO--(BUSINESS WIRE)--Feb 7, 2012 - Illumina, Inc. today announced its financial results for the fourth quarter and fiscal year of 2011.PHILADELPHIA--(BUSINESS WIRE)--Feb 7, 2012 - Lannett Company, Inc. today reported financial results for the fiscal 2012 second quarter and six months ended December 31, 2011.ALISO VIEJO, Calif., Feb. 7, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today reported financial results for the three months ended December 31, 2011.
Search the Site
Custom Search
